GlassScriptPhysician profile
Hind F Hamdan
NPI 1316989098
$4,028.24
in general payments reported to CMS, 2019-2025
49 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,384 · 2020: $735 · 2021: $910.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $341.29 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $295.40 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $285.46 | 2019-2021 | |
| Genentech USA, INC. | $265.59 | 2019-2021 | |
| Janssen Biotech, INC. | $260.30 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.77 | 2019-2021 | |
| Pfizer INC. | $173.16 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $172.52 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $145.18 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $116.31 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $99.58 | 2019-2021 | |
| Abbvie INC. | $92.51 | 2019-2021 | |
| Lilly USA, LLC | $90.13 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $89.79 | 2019-2021 |
Show all 49 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hind Hamdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.